Mapping Research Trends of Medications for Multidrug-Resistant Pulmonary Tuberculosis Based on the Co-Occurrence of Specific Semantic Types in the MeSH Tree: A Bibliometric and Visualization-Based Analysis of PubMed Literature (1966–2020)

References

• Zink AR, Sola C, Reischl U, et al. Characterization of Mycobacterium tuberculosis Complex DNAs from Egyptian Mummies by Spoligotyping. J Clin Microbiol. 2003;41(1):359–367. doi:10.1128/JCM.41.1.359-367.2003
   PubMed Web of Science ®Google Scholar
• Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656. doi:10.1016/S0140-6736(19)30308-3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022. Accessed June 29, 2023.
   Google Scholar
• World Health Organization. The End TB Strategy. Geneva: World Health Organization; 2015. Available from: https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy. Accessed June 29, 2023.
   Google Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240007048. Accessed June 29, 2023.
   Google Scholar
• Liu YG, Matsumoto M, Ishida H, et al. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis. 2018;111:20–30. doi:10.1016/j.tube.2018.04.008
   PubMed Web of Science ®Google Scholar
• Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998;66(4):1277–1281. doi:10.1128/IAI.66.4.1277-1281.1998
   PubMed Web of Science ®Google Scholar
• Singh L, Dua K, Kumar S, Kumar D, Majhi S. Targeting Molecular and Cellular Mechanisms in Tuberculosis. In: Dua K, Löbenberg R, Malheiros Luzo ÂC, Shukla S, Satija S, editors. Targeting Cellular Signalling Pathways in Lung Diseases. Singapore: Springer; 2021:37–353. doi:10.1007/978-981-33-6827-9_14
   Google Scholar
• Borah P, Deb PK, Venugopala KN, et al. Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti-tb drugs, treatment regimens and host- directed therapies. Curr Top Med Chem. 2021;21(6):547–570. doi:10.2174/1568026621999201211200447
   PubMed Web of Science ®Google Scholar
• Ntoumi F, Kaleebu P, Macete E, et al. Taking forward the World TB Day 2016 theme ‘Unite to End Tuberculosis’ for the WHO Africa Region. Int J Infect Dis. 2016;46:34–37. doi:10.1016/j.ijid.2016.03.003
   PubMed Web of Science ®Google Scholar
• Grange J, Story A, Zumla A. Tuberculosis in disadvantaged groups. Curr Opin Pulm Med. 2001;7(3):160–164. doi:10.1097/00063198-200105000-00008
   PubMedGoogle Scholar
• Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–823. doi:10.1056/NEJMoa2119430
   PubMed Web of Science ®Google Scholar
• Edwards BD, Field SK. The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis. Drugs. 2022;82(18):1695–1715. doi:10.1007/s40265-022-01817-w
   PubMedGoogle Scholar
• Dheda K, Gumbo T, Maartens G, et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820–826. doi:10.1016/S2213-2600(19)30263-2
   PubMed Web of Science ®Google Scholar
• Kamara RF, Saunders MJ, Sahr F, et al. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study. Lancet Glob Health. 2022;10(4):e543–e554. doi:10.1016/S2214-109X(22)00004-3
   PubMed Web of Science ®Google Scholar
• Sweileh WM, AbuTaha AS, Sawalha AF, et al. Bibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015). Multidiscip Respir Med. 2017;11:45. doi:10.1186/s40248-016-0081-0
   PubMedGoogle Scholar
• Kashyap V. The UMLS semantic network and the semantic web. AMIA Annu Symp Proc. 2003;2003:351–355.
   PubMedGoogle Scholar
• Fang L, Zhou X, Cui L. Biclustering high-frequency MeSH terms based on the co-occurrence of distinct semantic types in a MeSH tree. Scientometrics. 2020;124:1179–1190. doi:10.1007/s11192-020-03496-4
   Web of Science ®Google Scholar
• Yu G. Using meshes for MeSH term enrichment and semantic analyses. Bioinformatics. 2018;34(21):3766–3767. doi:10.1093/bioinformatics/bty410
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. Tree View. Available from: https://meshb.nlm.nih.gov/treeView. Accessed July 6, 2023.
   Google Scholar
• Zhou XB User’s guide to the “pubMR” package. GitHub; 2021. Available from: https://github.com/xizhou/pubMR. Accessed June 29, 2023.
   Google Scholar
• Liu Y, Wang Y, Li M. An empirical analysis for the applicability of the methods of definition of high-frequency words in word frequency analysis. Digi Lib Forum. 2017;9:42–49. doi:10.3772/j.issn.1673-2286.2017.09.007
   Google Scholar
• Li F, Li M, Guan P, Ma S, Cui L. Mapping publication trends and identifying hot spots of research on Internet health information seeking behavior: a quantitative and co-word biclustering analysis. J Med Internet Res. 2015;17(3):e81. doi:10.2196/jmir.3326
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
   PubMed Web of Science ®Google Scholar
• Kleinberg J. Bursty and hierarchical structure in streams. Data Min Knowl Disc. 2003;7(4):373–397. doi:10.1023/a:1024940629314
   Web of Science ®Google Scholar
• Chen CM. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57(3):359–377. doi:10.1002/asi.20317
   Web of Science ®Google Scholar
• Yitbarek K, Abraham G, Girma T, Tilahun T, Woldie M. The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic. Vaccine. 2020;38(41):6374–6380. doi:10.1016/j.vaccine.2020.08.018
   PubMed Web of Science ®Google Scholar
• Wangoo A, Brown IN, Marshall BG, Cook HT, Young DB, Shaw RJ. Bacille Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma). Clin Exp Immunol. 2000;119(1):92–98. doi:10.1046/j.1365-2249.2000.01100.x
   PubMed Web of Science ®Google Scholar
• Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001;2(3):164–168. doi:10.1186/rr54
   PubMed Web of Science ®Google Scholar
• Coban AY, Deveci A, Sunter AT, Martin A. Nitrate reductase assay for rapid detection of isoniazid, rifampin, ethambutol, and streptomycin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Clin Microbiol. 2014;52(1):15–19. doi:10.1128/JCM.01990-13
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Sung JC, Muttil P, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in Guinea pigs. Antimicrob Agents Chemother. 2010;54(4):1436–1442. doi:10.1128/AAC.01471-09
   PubMed Web of Science ®Google Scholar
• Ignatius EH, Abdelwahab MT, Hendricks B, et al. Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrob Agents Chemother. 2021;65(2):e01196–20. doi:10.1128/AAC.01196-20
   PubMed Web of Science ®Google Scholar
• Stancil SL, Mirzayev F, Abdel-Rahman SM. Profiling Pretomanid as a Therapeutic Option for TB Infection: evidence to Date. Drug Des Devel Ther. 2021;15:2815–2830. doi:10.2147/DDDT.S281639
   PubMed Web of Science ®Google Scholar
• Ignatius EH, Dooley KE. New Drugs for the Treatment of Tuberculosis. Clin Chest Med. 2019;40(4):811–827. doi:10.1016/j.ccm.2019.08.001
   PubMed Web of Science ®Google Scholar
• Mirsaeidi SM, Tabarsi P, Edrissian MO, et al. Primary multi-drug resistant tuberculosis presented as lymphadenitis in a patient without HIV infection. Monaldi Arch Chest Dis. 2004;61(4):244–247. doi:10.4081/monaldi.2004.690
   PubMedGoogle Scholar
• Goh TL, Towns CR, Jones KL, Freeman JT, Wong CS. Extensively drug-resistant tuberculosis: new Zealand’s first case and the challenges of management in a low-prevalence country. Med J Aust. 2011;194(11):602–604. doi:10.5694/j.1326-5377.2011.tb03115.x
   PubMed Web of Science ®Google Scholar
• Chahed H, Hachicha H, Berriche A, et al. Paradoxical reaction associated with cervical lymph node tuberculosis: predictive factors and therapeutic management. Int J Infect Dis. 2017;54:4–7. doi:10.1016/j.ijid.2016.10.025
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu D, Chen S, Han S, Xu S. Analysis of Research Hotspots in the Field of Global Medical Research Based on Natural Index. J China Soc Sci Tech Info. 2019;38(11):1129–1137. doi:10.3772/j.issn.1000-0135.2019.11.001
   Google Scholar
• Isakova J, Sovkhozova N, Vinnikov D, et al. Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic. BMC Microbiol. 2018;18(1):22. doi:10.1186/s12866-018-1168-x
   PubMedGoogle Scholar
• Mahwire TC, Zunza M, Marukutira TC, Naidoo P. Impact of Xpert MTB/RIF assay on multidrug-resistant tuberculosis treatment outcomes in a health district in South Africa. S Afr Med J. 2019;109(4):259–263. doi:10.7196/SAMJ.2019.v109i4.13180
   PubMed Web of Science ®Google Scholar
• Wilton P, Smith RD, Coast J, Millar M, Karcher A. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa. Int J Tuberc Lung Dis. 2001;5(12):1137–1142.
   PubMed Web of Science ®Google Scholar
• Franke MF, Khan P, Hewison C, et al. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021;203(1):111–119. doi:10.1164/rccm.202001-0135OC
   PubMed Web of Science ®Google Scholar
• Crespo JA, Herranz N, Li YR, Ruiz-Castillo J. The effect on citation inequality of differences in citation practices at the web of science subject category level. J Assoc Inf Sci. 2014;65(6):1244–1256. doi:10.1002/asi.23006
   Web of Science ®Google Scholar
• Xu S, Xu D, Wen L, et al. Integrating Unified Medical Language System and Kleinberg’s Burst Detection Algorithm into Research Topics of Medications for Post-Traumatic Stress Disorder. Drug Des Devel Ther. 2020;14:3899–3913. doi:10.2147/DDDT.S270379
   PubMed Web of Science ®Google Scholar
• Moulding TS, Le HQ, Rikleen D, Davidson P. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int J Tuberc Lung Dis. 2004;8(6):743–748.
   PubMed Web of Science ®Google Scholar
• Kayigire XA, Friedrich SO, van der Merwe L, Diacon AH. Acquisition of Rifampin Resistance in Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2017;61(4):e02220–16. doi:10.1128/AAC.02220-16
   PubMed Web of Science ®Google Scholar
• Dawson R, Diacon A. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs. 2013;22(7):927–932. doi:10.1517/13543784.2013.801958
   PubMed Web of Science ®Google Scholar